Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 28, 2006

AskBio and GSK Ink Gene Therapy Agreement

  • Asklepios Biopharmaceutical entered into a cross license agreement with GlaxoSmithKline to develop and commercialize gene therapy-based treatments.

    Through the agreement, AskBio will gain exclusive access to selected recombinant adeno-associated virus vector serotypes that GSK licensed from the University of Pennsylvania for the treatment of three orphan drug indications, including muscular dystrophy, heart failure suffered by muscular dystrophy patients, and hemophilia B.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »